Pascal COLOSETTI

Présentation

Professional experience

53 publications (December 15th, 2020)

2848 citations

H-Index: 23

2016-Today Research engineer within Inserm U1060-INRAe 1397-CarMeN (H. Vidal, Lyon, France): expertise in studying extracellular vesicles from different origins (eukaryotes and plants)

Director of the European School for the Study of Extracellular Vesicles (ESSEV, @EV_School_ESSEV)

2012-2017 Member of the Inserm Scientific Council

2001-2016 Research engineer within Inserm U1065-C3M (P. Auberger, Nice, France): Extracellular vesicles (microvesicles and exosomes) in cancer, chemoresistance and inflammation

1997-2001 Research engineer within Inserm U442 (J.-P. Mauger, Orsay, France): InsP3R expression and regulation during cell polarization

Diplomas and qualifications

2011 International Cancer Technology Transfer fellow at the Krefting Research Centre-Göteborg University, (Prof. J. Lötvall, Sweden) (UICC-ICRETT grant)

2008 Inter-university diploma (DIU) on acquired chromosomal pathologies (Bordeaux, Grenoble, Lille, Lyon, Marseille, Nice and Paris-Sud Universities)

2000 Transgenesis and homologous recombination diploma (Paris 6 University)

1994-1997 Postdoctoral fellow at the Laboratoire de Recherche en Oncologie of the Centre Alexis Vautrin (Nancy, France): Anticancer treatment resistance (Prof. J.-L. Merlin)

1991-1994 Postdoctoral fellow at the Ludwig Institute for Cancer Research (Uppsala, Sweden): TGF-beta activation and LTBP expression (Prof. C.-H. Heldin and Prof. K. Miyazono)

1991-1987 PhD in Biomedical Engineering at the Inserm U284 (Nancy University, France): TGF-beta 1 purification, a human platelet derived growth factor (C. Rivat and Prof. J.F. Stoltz)

After completing my PhD on the TGF-beta 1 purification, a human platelet derived growth factor, at the Inserm U284 in Nancy, I was as a postdoctoral fellow at the Ludwig Institute for Cancer Research in Uppsala on TGF-beta activation and LTBP expression; followed by an other fellowship at the Laboratoire de Recherche en Oncologie (Centre Alexis Vautrin in Nancy) coordinating a cancer treatment resistance project.

I then got a permanent position as research engineer at the Inserm U442 in Orsay to study the InsP3R expression during cell polarization.

I next joined the Inserm U1065-C3M in Nice involved in cell death, differentiation, inflammation and cancer; last years, I developed skills in the characterization of extracellular vesicles (microvesicles, exosomes...) in cancer, chemoresistance and inflammation.

I'm now part of the Inserm U1060-INRAe 1397-CarMeN in Lyon to study extracellular vesicles in metabolic disorders, founding and directing the European School for the Study of Extracellular Vesicles (ESSEV, @EV_School_ESSEV).

Publications

Article dans une revue (12)

Comparison of antioxidant efficiencies in oil‐in‐water emulsion using extracellular vesicles from olive co‐products or liposomes as antioxidants carriers Bruno Baréa,Nathalie Barouh,Amal Fenaghra,Pascal Colosetti,Jérôme Lecomteet al. Journal of the American Oil Chemists' Society, 2025, 102 (2), pp.323-337. ⟨10.1002/aocs.12887⟩ Article dans une revue hal-04677987v1
Extracellular vesicles from olive wastewater and pomace by‐products: Isolation, characterization of their lipid and phenolic profiles, and evaluation of their radical scavenging activity Nathalie Barouh,Amal Fenaghra,Pascal Colosetti,Jérôme Lecomte,Bruno Baréaet al. European Journal of Lipid Science and Technology, 2024, 126 (10), pp.2400019. ⟨10.1002/ejlt.202400019⟩ Article dans une revue hal-04701823v1
Use of Nanovesicles from Orange Juice to Reverse Diet-Induced Gut Modifications in Diet-Induced Obese Mice Emmanuelle Berger,Pascal Colosetti,Audrey Jalabert,Emmanuelle Meugnier,Oscar Wiklanderet al. Molecular Therapy - Methods and Clinical Development, 2020, 18, pp.880-892. ⟨10.1016/j.omtm.2020.08.009⟩ Article dans une revue hal-02952992v1
Lysosomal acid ceramidase ASAH1 controls the transition between invasive and proliferative phenotype in melanoma cells Justine Leclerc,David Garandeau,Charlotte Pandiani,Céline Gaudel,Karine Billeet al. Oncogene, 2019, 38 (8), pp.1282-1295. ⟨10.1038/s41388-018-0500-0⟩ Article dans une revue inserm-02529819v1
The oncogenic tyrosine kinase Lyn impairs the pro-apoptotic function of Bim. Lazaro E Aira,Elodie Villa,Pascal Colosetti,Parvati Gamas,Laurie Signettiet al. Oncogene, 2018, 37 (16), pp.2122 - 2136. ⟨10.1038/s41388-017-0112-0⟩ Article dans une revue inserm-01814383v1
BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice Mohamed Amine Hamouda,Arnaud Jacquel,Guillaume Robert,Alexandre Puissant,Valentine Richezet al. Journal of Experimental Medicine, 2016, [Epub ahead of print]. ⟨10.1084/jem.20150983⟩ Article dans une revue inserm-01353362v1
Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux Sandy Giuliano,Yann Cormerais,Maeva Dufies,Renaud Grépin,Pascal Colosettiet al. Autophagy, 2015, 11 (10), pp.1891-1904. ⟨10.1080/15548627.2015.1085742⟩ Article dans une revue hal-02108861v1
Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Sébastien Grosso,Alexandre Puissant,Maeva Dufies,Pascal Colosetti,Arnaud Jacquelet al. Molecular Cancer Therapeutics, 2009, 8 (7), pp.1924-33. ⟨10.1158/1535-7163.MCT-09-0168⟩ Article dans une revue hal-00419091v1
The caspase-cleaved form of LYN mediates a psoriasis-like inflammatory syndrome in mice. Sandrine Marchetti,Parvati Gamas,Nathalie Belhacène,Sebastien Grosso,Ludivine A Pradelliet al. EMBO Journal, 2009, 28 (16), pp.2449-60. ⟨10.1038/emboj.2009.183⟩ Article dans une revue hal-00419195v1
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Issam Ben Sahra,Kathiane Laurent,Agnès Loubat,Sophie Giorgetti Peraldi,Pascal Colosettiet al. Oncogene, 2008, 27 (25), pp.3576-86. ⟨10.1038/sj.onc.1211024⟩ Article dans une revue inserm-00277135v1
Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Frederic Luciano,Arnaud Jacquel,Pascal Colosetti,Magali Herrant,Sebastien Cagnolet al. Oncogene, 2003, 22 (43), pp.6785-93. ⟨10.1038/sj.onc.1206792⟩ Article dans une revue hal-00323924v1
The type 3 inositol 1,4,5-trisphosphate receptor is concentrated at the tight junction level in polarized MDCK cells P. Colosetti,R.E. Tunwell,C. Cruttwell,J.P. Arsanto,J.P. Maugeret al. Journal of Cell Science, 2003, 116, pp.2791-2803 Article dans une revue hal-00306513v1

Communication dans un congrès (1)

Extracellular vesicles from olive co-products: Isolation, characterization and antioxidant activity Amal Fenaghra,Pascal Colosetti,Jérôme Lecomte,Bruno Barea,Nathalie Barouhet al. 17. Euro Fed Lipid Congress, Oct 2019, Seville, Spain Communication dans un congrès hal-02356668v1

Thèse (1)

Contribution à la purification de facteurs de croissance humains d'origine plaquettaire : le Transforming Growth Factor-Beta 1 (TGF-[bêta]1) Pascal Colosetti Biochimie, Biologie Moléculaire. Université Henri Poincaré - Nancy 1, 1991. Français. ⟨NNT : 1991NAN10436⟩ Thèse tel-01747167v1